No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TLSI TriSalus Life Sciences
- 5.980
- +0.210+3.64%
Trading Jun 17 13:07 ET
162.41MMarket Cap-2495P/E (TTM)
6.122High5.701Low17.22KVolume5.680Open5.770Pre Close100.85KTurnover0.10%Turnover RatioLossP/E (Static)27.16MShares16.24052wk High-4.65P/B99.77MFloat Cap3.32052wk Low--Dividend TTM16.68MShs Float16.240Historical High--Div YieldTTM7.30%Amplitude3.320Historical Low5.856Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $16
Maxim Group analyst Jason McCarthy maintains $TriSalus Life Sciences(TLSI.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 29
JonesTrading Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $16
JonesTrading analyst Justin Walsh maintains $TriSalus Life Sciences(TLSI.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 37.
TriSalus Life Sciences Presents Liver and Pancreatic Cancer Data at ASCO 2024
TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery (PEDD) technology with immunotherapy to transform treatment for patients with liver
Express News | TriSalus Life Sciences: Hepatic Arterial Infusion of Nelitolimod Associated With Encouraging Immunologic Activity in Patients With Hcc, ICC
Express News | TriSalus Life Sciences: Hepatic Arterial Infusion of Nelitolimod Well Tolerated
Express News | TriSalus Life Sciences Highlights Clinical Data From Phase 1B Perio-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 Asco Annual Meeting
Comments
$TriSalus Life Sciences(TLSI.US$ TriSalus Life Sciences Inc: Full Year Sales Growth Expected to Exceed 50%
$TriSalus Life Sciences(TLSI.US$ TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code![]()
5
15
$TriSalus Life Sciences(TLSI.US$ Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications Via BusinessWire TLSI Share – New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier ...
2
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg